title: Targeting Tumor-Infiltrating B Cells in Cutaneous T-Cell Lymphoma.
authors.affiliation: University Hospital of Cologne, Cologne, Germany sebastian.theurich@uk-koeln.de.
authors.forename: Sebastian
authors.initials: S
authors.lastname: Theurich
authors.affiliation: University Hospital of Cologne, Cologne, Germany.
authors.forename: Max
authors.initials: M
authors.lastname: Schlaak
authors.affiliation: University Hospital of Cologne, Cologne, Germany.
authors.forename: Harold
authors.initials: H
authors.lastname: Steguweit
authors.affiliation: University Hospital of Cologne, Cologne, Germany.
authors.forename: Lukas C
authors.initials: LC
authors.lastname: Heukamp
authors.affiliation: University Hospital of Cologne, Cologne, Germany.
authors.forename: Kerstin
authors.initials: K
authors.lastname: Wennhold
authors.affiliation: University Hospital of Cologne, Cologne, Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Kurschat
authors.affiliation: University Hospital of Cologne, Cologne, Germany.
authors.forename: Anja
authors.initials: A
authors.lastname: Rabenhorst
authors.affiliation: University Hospital of Cologne, Cologne, Germany.
authors.forename: Karin
authors.initials: K
authors.lastname: Hartmann
authors.affiliation: University Hospital of Cologne, Cologne, Germany.
authors.forename: Hans
authors.initials: H
authors.lastname: Schlösser
authors.affiliation: University Hospital of Cologne, Cologne, Germany.
authors.forename: Alexander
authors.initials: A
authors.lastname: Shimabukuro-Vornhagen
authors.affiliation: University Hospital of Cologne, Cologne, Germany.
authors.forename: Udo
authors.initials: U
authors.lastname: Holtick
authors.affiliation: University Hospital of Cologne, Cologne, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Hallek
authors.affiliation: Johannes-Wessling-Hospital, Minden, Germany.
authors.forename: Rudolf
authors.initials: R
authors.lastname: Stadler
authors.affiliation: University Hospital of Cologne, Cologne, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: von Bergwelt-Baildon
mesh_terms: D000368:Aged; D018951:Antigens, CD20 / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D001706:Biopsy; D018450:Disease Progression; D017809:Fatal Outcome; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016246:Lymphocytes, Tumor-Infiltrating / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D012074:Remission Induction; D000069283:Rituximab / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab